Actively Recruiting
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
Led by Severance Hospital · Updated on 2024-12-27
200
Participants Needed
1
Research Sites
939 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.
CONDITIONS
Official Title
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 19 and 70 years
- Diagnosis of OCD by DSM-IV criteria
- Drug naive or drug free for more than 3 months
You will not qualify if you...
- Any neurological disorder
- Comorbid psychotic disorders
- Alcohol or other substance dependence within past 6 months
- Any evidence of brain diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yonsei Univ. Health System Severance Hospital
Seoul, South Korea, 120-752
Actively Recruiting
Research Team
S
Se Joo Kim, M.D.
CONTACT
J
Jee In Kang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here